Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration (TGA) to manufacture the Company's proprietary high-density microarray patch (HD-MAP) for clinical trials at its state-of-the-art biomedical facility in Brisbane. This achievement strengthens Vaxxas' leadership in next-generation vaccine delivery and follow…